It is well known that AHC patients harboring ATP1A3 mutations exhibit various forms of hyperkinetic non-paroxysmal movement disorders as chorea, dystonia, myoclonus, and ataxia, with a heterogeneous degree of severity. This evidence concerns the gene ATP1A3 and choreatic disease.